A legal path for debt relief when solvency fails
Johnson & Johnson has reached a landmark settlement to resolve about 76,000 talc-related claims alleging ovarian cancer, potentially ending a decade-long legal battle. The deal requires 95% court acceptance and could total well above $3 billion, with payments beginning in 2027 and continuing into 2028; total payout could rise to $7 billion or more depending on participation.
Johnson & Johnson has reached a settlement to resolve tens of thousands of talc-related claims. The deal covers about 76,000 claims, with initial payments of up to $3 billion next year and further payments in 2028, subject to 95% claimant participation. The agreement aims to end a decade-long court battle over asbestos-tainted talc products, while preserving the company’s broader mission to develop medicines and devices.
A Morgan Stanley analysis finds seven major tech companies have commitments worth $3 trillion for AI infrastructure off balance sheet, plus $1.7 trillion in other purchase commitments. The figures suggest heavy leverage and potential future revenue, with questions about when these obligations will appear on official balance sheets and how they will pay off.